STOCK TITAN

Sonnet BioTherapeutics Holdings, Inc. - SONN STOCK NEWS

Welcome to our dedicated page for Sonnet BioTherapeutics Holdings news (Ticker: SONN), a resource for investors and traders seeking the latest updates and insights on Sonnet BioTherapeutics Holdings stock.

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) is a clinical-stage biotechnology company based in Cranbury, New Jersey. The firm is pioneering the development of targeted immunotherapeutic drugs primarily aimed at treating cancers. Sonnet employs its proprietary FHAB (Fully Human Albumin Binding) technology, which utilizes a single-chain antibody fragment that binds to human serum albumin for targeted delivery to tumor and lymphatic tissues. This innovative platform enhances drug efficacy and safety by extending the half-life of therapeutic agents and concentrating them in the tumor microenvironment (TME).

Sonnet’s mission focuses on generating immuno-oncology candidates and advancing them to Phase II clinical assets. The company's current pipeline includes several promising products:

  • SON-080 - A low-dose IL-6 aimed at treating chemotherapy-induced peripheral neuropathy (CIPN).
  • SON-1210 - Combines IL-12 and IL-15 with Sonnet's FHAB for robust immune response targeting tumors.
  • SON-1010 - Consists of a single-chain IL-12 linked with the albumin-binding domain for enhanced targeting and efficacy in cancer treatment.

Recent achievements include the publication of preclinical data demonstrating the efficacy of SON-1210 in reducing tumor growth in melanoma models. Additionally, the company reported positive safety and tolerability results from Phase 1 studies of SON-1010 in healthy volunteers and cancer patients.

Sonnet's collaboration with Genentech for the combination study of SON-1010 and atezolizumab (Tecentriq) in platinum-resistant ovarian cancer is a significant milestone. Financially, the company has successfully leveraged tax credits and managed its cash runway effectively, projecting operations funding into the latter part of 2024.

The company is also actively exploring strategic alternatives to maximize stockholder value, having engaged Chardan Capital Markets to assist in evaluating potential business development, partnerships, acquisitions, or mergers.

Rhea-AI Summary

Sonnet BioTherapeutics Holdings, with ticker SONN, announced progress in its clinical pipeline and financial results for Q1 FY 2022. The company is set to initiate clinical studies for SON-1010 and SON-080 in Q2 2022, alongside completing R&D for a toxicity study for SON-1210. Financially, Sonnet held $19.4 million in cash, with R&D expenses increasing to $4.3 million from $3.9 million year-over-year. The net loss for the quarter was $6.2 million, a slight increase compared to the previous year's loss of $5.9 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
-
Rhea-AI Summary

Sonnet BioTherapeutics Holdings (NASDAQ:SONN) reported its fiscal year 2021 results, highlighting significant advancements in its therapeutic pipeline. The company announced promising data from preclinical studies for SON-1010 and SON-080, along with the identification of a new bispecific candidate, SON-1410. Financially, Sonnet raised approximately $27.6 million through a public offering, ending the fiscal year with $27.6 million in cash. R&D expenses rose to $16.6 million, reflecting ongoing development efforts. The CEO expressed confidence in the company's growth trajectory for 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.84%
Tags
-
Rhea-AI Summary

Sonnet BioTherapeutics has selected a new candidate, SON-1410 (IL18-FHAB-IL12), for development after successful comparisons in a mouse melanoma study. This candidate, integrating Interleukins 18 and 12, aims to target melanoma and renal cancers. An IND submission is expected in 2022. The study showed significant tumor reduction compared to placebo, with promising immune responses. Following a recent $30 million financing, Sonnet is focused on advancing its immuno-oncology pipeline, with manufacturing processes for SON-1410 already in progress.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.21%
Tags
none
Rhea-AI Summary

Sonnet BioTherapeutics Holdings (NASDAQ:SONN) announced a public offering of 35,294,117 shares at a price of $0.85 per share, projected to raise approximately $30 million before expenses. Each share comes with an investor warrant for one additional share at the same price. A 30-day over-allotment option for an additional 5,294,117 shares is available to underwriters. Funds will be allocated for research, clinical trials, and general corporate purposes. The offering is expected to close around August 24, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-48.36%
Tags
-
Rhea-AI Summary

Sonnet BioTherapeutics (NASDAQ:SONN) reported its fiscal Q3 2021 results, noting progress on its Fully Human Albumin Binding (FHAB) drug pipeline. With IND submissions for SON-1010 and SON-080 anticipated by year-end 2021, the company is focused on increasing the efficacy of targeted therapies. The financing strategy generated $15.9 million through an at-the-market sale, enhancing R&D capabilities. As of June 30, 2021, cash on hand stood at $6 million, with R&D expenses rising to $3.9 million, reflecting heightened developmental activity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.2%
Tags
-
Rhea-AI Summary

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) has rescheduled its annual stockholders meeting to July 15, 2021, at 9:00 a.m. Eastern Time, to be conducted virtually. The meeting will include discussions on key proposals such as the election of directors and appointment of the independent auditing firm for the fiscal year ending September 30, 2021.

Sonnet is focused on developing innovative biologic drugs using its proprietary FHAB technology, which enhances drug efficacy through targeted delivery mechanisms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
none
Rhea-AI Summary

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) announced the issuance of U.S. Patent No. 11,028,166 for its Fully Human Albumin Binding (FHAB™) technology, valid until March 2039. This patent protects therapeutic fusion proteins designed for tumor targeting and extended pharmacokinetics. CEO Pankaj Mohan emphasized its significance in differentiating from competitors and validating their product pipeline.

Sonnet's FHAB platform enhances penetration and retention in tumors, showcasing potential for improved efficacy against wild type cytokines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) announced positive results from a preclinical GLP repeat-dose study of SON-1010, a proprietary Interleukin 12 biologic, in nonhuman primates. The No Observed Adverse Event Level was over 50 times the expected human dose, with no cytokine release syndrome noted. The pharmacokinetic profile showed a half-life of approximately 40 hours, enhancing therapeutic potential. Additionally, significant increases in Interferon-γ, an anti-tumor cytokine, were recorded. These findings support the safety and efficacy of SON-1010 for future clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.47%
Tags
none
-
Rhea-AI Summary

Sonnet BioTherapeutics Holdings (NASDAQ:SONN) has signed a licensing agreement with New Life Therapeutics (NLT) for low-dose Interleukin 6 to treat Diabetic Peripheral Neuropathy (DPN) in ASEAN countries. The deal includes an upfront payment of $1 million and up to $20 million in milestone payments, along with royalties of 12% to 30% on net sales. NLT will manage a Phase 1b/2a clinical trial, set to begin in the second half of 2021. This partnership aims to address rising diabetes rates in the region and bring innovation to neuropathy treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.66%
Tags
none
Rhea-AI Summary

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) provided an update on its ongoing programs. The company has completed GLP toxicity studies for SON-1010 and SON-080, with plans to initiate clinical trials in the second half of 2021. A partnership with New Life Therapeutics for SON-081 aims to advance it into clinical trials. Sonnet is actively developing several candidates, including SON-1210 and SON-2014, with IND submissions planned. Additionally, the company received a Notice of Allowance for its FHAB delivery technology patent, strengthening its intellectual property portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.86%
Tags
none

FAQ

What is the current stock price of Sonnet BioTherapeutics Holdings (SONN)?

The current stock price of Sonnet BioTherapeutics Holdings (SONN) is $1.44 as of December 23, 2024.

What is the market cap of Sonnet BioTherapeutics Holdings (SONN)?

The market cap of Sonnet BioTherapeutics Holdings (SONN) is approximately 4.6M.

What is the primary focus of Sonnet BioTherapeutics?

Sonnet BioTherapeutics focuses on developing targeted immunotherapeutic drugs primarily for cancer treatment using its proprietary FHAB technology.

Where is Sonnet BioTherapeutics based?

Sonnet BioTherapeutics is based in Cranbury, New Jersey.

What is FHAB technology?

FHAB (Fully Human Albumin Binding) technology utilizes a single-chain antibody fragment that binds to human serum albumin for targeted drug delivery to tumor and lymphatic tissues.

What are some of Sonnet's leading drug candidates?

Sonnet's leading drug candidates include SON-080 for CIPN, SON-1210 for dual IL-12 and IL-15 targeting, and SON-1010 for targeted IL-12 delivery to tumors.

What recent achievements has Sonnet BioTherapeutics made?

Recent achievements include the publication of preclinical data on SON-1210's efficacy in reducing tumor growth, and positive safety results from Phase 1 studies of SON-1010.

What financial strategies has Sonnet employed?

Sonnet has optimized its operations by leveraging tax credits and managing its cash runway to extend funding into the latter part of 2024.

What collaborations is Sonnet involved in?

Sonnet is collaborating with Genentech to study the combination of SON-1010 and atezolizumab (Tecentriq) in platinum-resistant ovarian cancer.

What strategic alternatives is Sonnet exploring?

Sonnet is exploring a range of strategic alternatives, including business development, partnerships, acquisitions, and mergers, to maximize stockholder value.

Who is advising Sonnet on strategic alternatives?

Sonnet has engaged Chardan Capital Markets as its financial advisor to assess potential strategic alternatives.

What is the mission of Sonnet BioTherapeutics?

Sonnet's mission is to generate immuno-oncology candidates and advance them into Phase II clinical assets, leveraging its unique IP-driven platform.

Sonnet BioTherapeutics Holdings, Inc.

Nasdaq:SONN

SONN Rankings

SONN Stock Data

4.63M
2.53M
4.22%
0.61%
4.2%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PRINCETON